XOMA (XOMA) to Release Earnings on Friday

XOMA (NASDAQ:XOMA) will likely be issuing its quarterly earnings data before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.29) per share and revenue of $8.75 million for the quarter.

XOMA Stock Performance

Shares of XOMA stock opened at $21.69 on Friday. XOMA has a 12-month low of $20.87 and a 12-month high of $35.00. The firm has a market capitalization of $255.57 million, a price-to-earnings ratio of -6.23 and a beta of 0.90. The business has a 50 day simple moving average of $25.61 and a 200 day simple moving average of $27.81. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52.

Wall Street Analyst Weigh In

XOMA has been the subject of a number of recent analyst reports. HC Wainwright decreased their price objective on XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a report on Monday, February 3rd. StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a report on Tuesday, February 25th.

Insider Buying and Selling at XOMA

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.20% of the stock is currently owned by corporate insiders.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.